Pila Pharma in Sweden

Clinical Trials sponsored by Pila Pharma

About Pila Pharma

Pila Pharma is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden. The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent. XEN-D0501 is a synthetic small molecule that was in-licensed in 2016. Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups. Pila Pharma has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.